Safety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction

Dan Haberman
Rodrigo Estévez-Loureiro
Tomas Benito-Gonzalez
Paolo Denti
Dabit Arzamendi

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/cardiology_articles
Authors
Dan Haberman, Rodrigo Estévez-Loureiro, Tomas Benito-Gonzalez, Paolo Denti, Dabit Arzamendi, Marianna Adamo, Xavier Freixa, Luis Nombela-Franco, Pedro Villablanca, Lian Krivoshei, Neil Fam, Konstantinos Spargias, Andrew Czarnecki, Isaac Pascual, Fabien Praz, Doron Sudarsky, Arthur Kerner, Vlasis Ninios, Marco Gennari, Ronen Beer, Leor Perl, Haim Danenberg, Lion Poles, Sara Shimoni, Sorel Goland, Berenice Caneiro-Queija, Salvatore Scianna, Igal Moaraf, Davide Schiavi, Claudia Scardino, Noé Corpataux, Julio Echarte-Morales, Michael Chrissoheris, Estefanía Fernández-Peregrina, Mattia Di Pasquale, Ander Regueiro, Carlos Vergara-Uzcategui, Andres Ifíguez-Romo, Felipe Fernández-Vázquez, Danny Dvir, Maurizio Taramasso, and Mony Shuvy
Safety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction

Dan Haberman 1,*,†, Rodrigo Estévez-Loureiro 2,†, Tomas Benito-Gonzalez 3,*, Paolo Dentì 4,*, Dabit Arzamendi 5, Marianna Adamo 6, Xavier Freixa 7, Luis Nombela-Franco 8,*, Pedro Villablanch 9, Lian Krivoshei 10, Neil Fam 11, Konstantinos Spargias 12, Andrew Czarnecki 13, Isaac Pascual 14,*, Fabien Praz 15, Doron Sudarsky 16, Arthur Kerner 17, Vlasis Ninios 18, Marco Gennari 19,20, Ronen Beer 21,*, Leor Perl 22,*, Haim Danenberg 21, Lion Poles 1, Sara Shimoni 1, Sorel Goland 1, Berenice Canéreo-Queija 2, Salvatore Scianna 20, Igal Moorad 10, Davide Schiavi 4,*, Claudia Scardino 23, Noé Corpataux 18, Julio Echarte-Morales 3, Michael Chrissosheris 12, Estefania Fernández-Peregrina 5,*, Mattia Di Pasquale 6, Ander Regueiro 7,*, Carlos Vergara-Uzcategui 8,*, Andres Iñiguez-Romo 2, Felipe Fernández-Vázquez 3,*, Danny Dvir 24, Maurizio Taramasso 20,*,† and Mony Shuvy 21,24,†

Heart Center, Kaplan Medical Center, Affiliated to the Hebrew University, Jerusalem 9190501, Israel; Lion_P@clalit.org.il (L.P.); sarah_s2@clalit.org.il (S.S.); Sorel_G@clalit.org.il (S.G.)

Received: 25 February 2021
Accepted: 13 April 2021
Published: 22 April 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abstract: Patients with severe mitral regurgitation (MR) after myocardial infarction (MI) have an increased risk of mortality. Transcatheter mitral valve repair may therefore be a suitable therapy. However, data on clinical outcomes of patients in an acute setting are scarce, especially those with reduced left ventricle (LV) dysfunction. We conducted a multinational, collaborative data analysis from 21 centers for patients who were, within 90 days of acute MI, treated with MitraClip due to severe MR. The cohort was divided according to median left ventricle ejection fraction (LVEF)—35%. Included in the study were 105 patients. The mean age was 71 ± 10 years. Patients in the LVEF < 35% group were younger but with comparable Euroscore II, multivessel coronary artery disease, prior MI and coronary artery bypass graft surgery. Procedure time was comparable and acute success rate was high in both groups (94% vs. 90%, \(p = 0.728\)). MR grade was significantly reduced in both groups along with an immediate reduction in left atrial V-wave, pulmonary artery pressure and improvement in New York Heart Association (NYHA) class. In-hospital and 1-year mortality rates were not significantly different between the two groups (11% vs. 7%, \(p = 0.51\) and 19% vs. 12%, \(p = 0.49\)) and neither was the 3-month re-hospitalization rate. In conclusion, MitraClip intervention in patients with acute severe functional mitral regurgitation (FMR) due to a recent MI in an acute setting is safe and feasible. Even patients with severe LV dysfunction may benefit from transcatheter mitral valve intervention and should not be excluded.

Keywords: mitral regurgitation; percutaneous mitral valve repair; acute myocardial infarction; left ventricle dysfunction

1. Introduction

Mitral regurgitation (MR) complicating acute Myocaridial Infarction (MI) can be the result of papillary muscle rupture (Primary) or imbalance between closing and tethering forces (Functional). Primary MR in this acute setting is a medical emergency often requires emergent intervention [1]. Functional mitral regurgitation (FMR) usually develops over the course of days and is associated with adverse outcomes [2]. Currently, medical therapy is the mainstay approach for this condition. However, some patients remain very symptomatic with prolonged hospitalization and frequent heart failure (HF) admissions [3].

Data obtained from large-scale registries suggest that percutaneous transcatheter edge-to-edge mitral valve repair implantation with MitraClip device improves functional capacity and quality of life [4–7]. Furthermore, the recent randomized trial entitled, ‘Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation’ (COAPT) showed that MitraClip improved clinical outcomes, including mortality in patients with severe FMR, when compared to medical therapy alone [8]. Conversely, the results of the ‘Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients with Severe Secondary Mitral Regurgitation’ (MITRA-FR) illustrated that enrolled patients with lower LVEF showed no clinical benefit from the MitraClip procedure in an advanced HF population [9], thereby suggesting that patients with lower LVEF may benefit less from the MitraClip procedure.

Focusing on patients with reduced left ventricle (LV) function, previous studies have addressed this issue with mixed results. In the German transcatheter mitral valve interventions (TRAMI) registry, the clinical benefit for patients with severely reduced LV function was comparable to patients with preserved LV [6]. However, a recent paper by Pascual
et al. showed that patients in the LVEF > 30% group had better clinical outcomes [10]. Percutaneous edge-to-edge repair for functional MR was recently implemented in the American Heart Association 2020 clinical guidelines [11]. However, it is still not clear how effective it is for patients with a severe reduction in LV function. While the positive value of MitraClip implantation on outcomes in chronic severe symptomatic ischemic FMR was shown before [12], data regarding patients with severe acute ischemic FMR, who are generally not included in registries or in randomized trials, are lacking, especially in patients with severely reduced LV function.

Our group previously published two case series showing that the MitraClip procedure is safe in patients with pulmonary congestion due to severe functional MR complicating MI [13,14]. MR reduction was significant with favorable hemodynamics and clinical improvement. The mortality rate after 30 days was as low as 10%. A recent publication by our group showed that even patients in cardiogenic shock may benefit from percutaneous edge-to-edge repair [15].

However, it is unknown how effective the MitraClip procedure is in severe LV dysfunction patients in an acute setting.

2. Methods

The International Registry of MitraClip in Acute Mitral Regurgitation following acute myocardial infarction (IREMMI) was established to assess the safety and outcomes of patients who underwent MitraClip in an acute setting following MI. In this multinational, multicenter retrospective registry, we evaluated the short and intermediate outcomes based on left ventricle ejection fraction. The procedure was performed in 21 centers in Europe, North America and Israel using the MitraClip device (Abbott, Menlo Park, CA, USA).

2.1. Study Population

We included patients who were treated with the MitraClip device due to at least moderate to severe (3+) MR, within 90 days of acute myocardial infarction (MI) between January 2014 and January 2020. Although treated medically, patients remained symptomatic (NYHA class > 3) and were evaluated by a multidisciplinary team of a non-interventional cardiologist, an interventional cardiologist and a cardiothoracic surgeon. All patients were deemed to be high risk for surgery and therefore a MitraClip procedure was performed in order to allow recovery. Patients who were anatomically unsuitable for edge-to-edge mitral valve repair were excluded. We evaluated immediate, 3-month and 1-year outcomes in those patients.

2.2. Echocardiographic Evaluation

The severity of MR, left ventricle ejection fraction (LVEF), pulmonary artery pressure (PAP) and Mitral valve (MV) gradient were measured and graded according to the American Society of Echocardiography guidelines [16–18]. The severity of MR was assessed with an integrated multiparametric visual evaluation tool in accordance with standard clinical practice (incorporating 2D, spectral and color Doppler images), using an ordinal scale (grading 0– no MR, 1+ mild MR, 2+ moderate MR, 3+ moderate to severe MR, 4+ severe MR). A transesophageal echocardiogram (TEE) was completed in all patients prior to the procedure. MR grade, Mitral valve area (MVA) and MV gradient, calcium at grasping area and coaptation features were assessed in order to evaluate MitraClip feasibility.

2.3. MitraClip

A MitraClip procedure was performed under general anesthesia; fluoroscopy and transesophageal echocardiography (TEE) were routinely used for guidance. After transseptal puncture, the delivery system was advanced to the left atrium (LA), LV and retracted back to grasp the anterior and posterior leaflets. Procedural success was defined as the successful grasping of the anterior and posterior leaflets together with a reduction of at
least two MR grades. V-wave and left atrial pressures (LAP) were measured and recorded immediately before and after MitraClip implantation.

2.4. Outcomes

Procedural and clinical adverse events during follow-up were defined according to the Mitral Valve Academic Research Consortium (MVARC) [13]. Outcomes of interest were procedural success, safety, hospital discharge, clinical outcomes and hemodynamics. Acute procedural success was defined as successful implantation of one or more clips with a reduction of the MR to <2+. Safety outcomes included procedural and periprocedural complications, namely, clip detachment, cerebrovascular event, MI, bleeding requiring transfusion and cardiac tamponade and urgent cardiovascular surgery. Clinical outcomes included weaning from mechanical ventilation and/or an LV support device and an NYHA class at follow-up. Hemodynamic parameters, LAP and V-wave were measured during the procedure. In cases where right heart catheterization was used, pulmonary artery wedge pressure (PCWP) was measured simultaneously with the procedure. After discharge, patients were followed up by individual centers in outpatient clinic visits in which clinical evaluation and echocardiography were performed.

2.5. Statistical Analysis

Our analyses were performed using the entire cohort, drawing comparisons between patients with EF lower or higher than 35%. Patient characteristics are reported according to variable properties. Categorical variables (ex. MR grade) are reported as % (n), and differences between subgroups were tested, when appropriate, using the chi-square test of Fischer’s exact test. Continuous variables (ex. LVEF, PCWP, V-wave, sPAP) are reported according to their distribution. Those with a normal distribution are reported as mean (±standard deviation), and differences between subgroups were tested using the student’s T-test. Those without a normal distribution are reported as median (interquartile range), and differences between subgroups were tested using the Mann-Whitney U. A p-value less than 0.05 was considered to be statistically significant. Kaplan-Meier estimates were used to calculate survival curves, which were adjusted to age and compared using the log-rank test. All clinical events were analyzed by time-to first event for Kaplan-Meier analysis. The IBM Statistical Package for the Social Sciences (SPSS) Statistics 26.0 (IBM Corp., Armonk, NY, USA) was utilized to perform the analyses.

3. Results

From January 2014 to January 2020, 105 patients were included in the registry.

3.1. Patient Characteristics

The mean age of patients was 70.5 ± 10.3 years and 50% were female. All patients had at least MR grade 3 before the intervention. Patients suffered pulmonary congestion despite initial medical therapy, including intravenous diuretics. Of the patients, 52 (55%) were in cardiogenic shock and were further supported by an intra-aortic balloon pump (IABP) or intravenous vasopressors, whilst 41 patients (43%) required mechanical ventilation unrelated to the procedure. The patient population was divided into two groups based on the median LVEF of 35%. The LVEF < 35% group included 47 patients, whilst LVEF ≥ 35% included 58 patients with a mean LVEF of 26 ± 6% and 44 ± 9%, p < 0.01, respectively.

Baseline characteristics are listed in Table 1. Patients in the LVEF < 35% group were younger when compared to patients with LVEF ≥ 35% (68.4 ± 9.1 vs. 72.4 ± 11.0, p = 0.05), as well as having a higher body–mass index (BMI) (27.9 ± 4.7 vs. 25.5 ± 5.3, p = 0.04). There was no difference in other risk factors for cardiovascular disease, past MI, past Coronary Artery Bypass Graft (CABG) or in the surgical risk assessment by Euroscore II.
Table 1. Baseline Patient Characteristics.

| Parameter | Total Population | LVEF < 35% | LVEF ≥ 35% | p-Value |
|-----------|-----------------|------------|------------|---------|
| n         | 105             | 47         | 58         |         |

Demographics

| Parameter | Total Population | LVEF < 35% | LVEF ≥ 35% | p-Value |
|-----------|-----------------|------------|------------|---------|
| Age, years | 70.5 ± 10.3     | 68.4 ± 9.1 | 72.4 ± 11.0 | 0.05    |
| Sex, Female, % (n) | 50 (53) | 43 (20) | 57 (33) | 0.17    |
| BMI (Kg/M²) | 26.5 ± 5.2      | 27.9 ± 4.7 | 25.5 ± 5.3 | 0.04    |
| Hypertension, % (n) | 70.5 (74) | 68.1 (32) | 70.7 (41) | 0.83    |
| Diabetes, % (n) | 45.7 (48) | 51.1 (24) | 41.4 (24) | 0.33    |
| Dyslipidemia, % (n) | 62.9 (66) | 70.0 (31) | 60.3 (35) | 0.69    |
| COPD, % (n) | 17.1 (18) | 19.1 (9) | 15.5 (9) | 0.80    |
| CKD ≥ grade 2, % (n) | 29.5 (31) | 25.5 (12) | 32.8 (19) | 0.82    |
| Prior stroke, % (n) | 13.3 (14) | 6.4 (3) | 19.0 (11) | 0.08    |
| Prior MI, % (n) | 55.2 (58) | 61.7 (29) | 50 (29) | 0.24    |
| Prior CABG, % (n) | 26.7 (28) | 23.4 (11) | 29.3 (17) | 0.51    |
| Euroscore 2, % | 17.2 ± 16.7 | 20.1 ± 18.5 | 14.9 ± 15.0 | 0.14    |

Presentation

| Parameter | Total Population | LVEF < 35% | LVEF ≥ 35% | p-Value |
|-----------|-----------------|------------|------------|---------|
| STEMI, % (n) | 71.4 (75) | 66.0 (31) | 75.9 (44) | 0.25    |
| Killip Class 3+, % (n) | 68.6 (72) | 78.7 (37) | 60.3 (35) | 0.06    |

Echocardiographic

| Parameter | Total Population | LVEF < 35% | LVEF ≥ 35% | p-Value |
|-----------|-----------------|------------|------------|---------|
| MR Grade 4+, % (n) | 81.0 (85) | 83.0 (39) | 79.3 (46) | 0.80    |
| Papillary muscle rapture, % (n) | 5.7 (6) | 2.1 (1) | 8.6 % (5) | 0.22    |
| Ejection Fraction (%) | 35.8 ± 11.9 | 25.8 ± 5.7 | 44 ± 8.9 | <0.01    |
| sPAP, mmHg | 53.6 ± 18.6 | 54.4 ± 16.1 | 53.1 ± 20.3 | 0.75    |

Coronary Angiography

| Parameter | Total Population | LVEF < 35% | LVEF ≥ 35% | p-Value |
|-----------|-----------------|------------|------------|---------|
| Multivessel disease, % (n) | 80 (84) | 83.0 (39) | 77.6 (45) | 0.63    |
| RCA, % (n) | 11 (5) | 41 (24) |         |         |
| LCX, % (n) | 32 (15) | 33 (19) |         | <0.01   |
| LAD, % (n) | 53 (25) | 22 (13) |         |         |
| PCI, % (n) | 94.3 (99) | 95.7 (45) | 95.7 (54) | 0.69    |
| Anterior | 51 (24) | 19 (11) |         |         |
| Inferior | 30 (14) | 59 (34) |         | <0.01   |
| Lateral and/or Posterior | 19 (9) | 22 (13) |         |         |

ICCU Status and Treatment

| Parameter | Total Population | LVEF < 35% | LVEF ≥ 35% | p-Value |
|-----------|-----------------|------------|------------|---------|
| Cardiogenic Shock | 54.3 (57) | 63.8 (30) | 46.6 (27) | 0.12    |
| Mechanical Ventilation | 42.9 (45) | 46.8 (22) | 39.7 (23) | 0.55    |
| Vasoactive medication | 42.9 (45) | 48.9 (23) | 37.9 (22) | 0.32    |
| Any MSD | 37.1 (39) | 42.6 (20) | 32.8 (19) | 0.32    |

Out of 105 patients, 75 presented with STEMI but there was no significant difference between the two groups (66% vs. 76%, respectively, p = 0.14). In both groups there was a high rate of multi-vessel disease (80% vs. 78%, p = 0.63). The common infarct related artery (IRA) was the LAD in the LVEF < 35% group (53% vs. 22%), and the RCA in the LVEF ≥ 35% group (41% vs. 11%, p < 0.01).

The anterior LV wall was involved in 51% of patients in the LVEF < 35% group vs. 19% of patients in the LVEF ≥ 35% group. Accordingly, the inferior wall was more involved in the LVEF ≥ 35% group (59% vs. 30%, p < 0.01).

3.2. Procedural and Safety Outcomes

Procedure characteristics, safety and outcomes are listed in Table 2.
Table 2. Procedure and Outcomes.

| Parameter                  | Total Population | LVEF < 35% | LVEF ≥ 35% | p-Value |
|----------------------------|-----------------|------------|------------|---------|
| n                          | 105             | 47         | 58         |         |
| Procedure Time, min        | 115 ± 90        | 122 ± 84   | 109 ± 95   | 0.51    |
| Major Complications        | 6.7 (7)         | 8.5 (4)    | 5.2 (3)    | 0.70    |
| MI to Procedure, days      | 27 ± 22         | 35 ± 26    | 20 ± 17    | <0.01   |
| Clips Implanted, mean      | 1.7 ± 0.7       | 1.8 ± 0.7  | 1.6 ± 0.6  | 0.22    |
| MR > 2 at discharge, % (n) | 8.6 (9)         | 8.5 (4)    | 8.6 (5)    | 1       |
| MV Gradient post           | 3.7 ± 1.7       | 3.7 ± 1.6  | 3.7 ± 1.8  | 0.91    |

Outcomes

| Procedure success          | 91.4 (96)       | 93.6 (44)  | 89.7 (52)  | 0.73    |
| In hospital mortality      | 8.6 (9)         | 10.6 (5)   | 6.9 (4)    | 0.51    |
| Major Complications        | 6.7 (7)         | 8.5 (4)    | 5.2 (3)    | 0.70    |
| Mortality at 3 months      | 11.4 (12)       | 14.9 (7)   | 8.6 (5)    | 0.50    |
| Rehospitalizations at 3 months | 13.3 (14) | 19.1 (9)  | 15.5 (9)   | 0.77    |
| 1-year mortality           | 15.2 (16)       | 19.1 (9)   | 12.1 (7)   | 0.49    |

Abbreviations: LVEF—Left Ventricle Ejection Fraction; MI—Myocardial Infarction; MO—Month; MR—Mitral Regurgitation; MV—Mitral Valve.

A MitraClip procedure was performed, on average, 27 ± 22 days after the date of the index MI. When drawing comparisons based on LVEF, procedures were delayed in the LVEF ≥ 35% group, where the MitraClip procedure was performed, on average, at 37 ± 26 days vs. 21 ± 18 days, \( p = 0.001 \) in the LVEF < 35% group. Procedure success was 91.4% (96 out of 105 patients). There was no significant difference between the two LVEF groups, 96% vs. 90%, \( p = 0.73 \). The procedure’s mean duration was 115 min ± 90 min. There was no difference in duration between the LVEF < 35% group (122 min ± 84 min) and the LVEF ≥ 35% group (109 min ± 95 min), \( p = 0.51 \). MR reduction to grade 1 was achieved in 64 patients and to 2+ in 32 patients (Figure 1). The grade of MR significantly decreased after the procedure, \( p < 0.01 \). No difference was observed between the two LV groups. One to four clips were implanted in each case; 42 patients were implanted with a single clip, 52 were implanted with two clips, 9 were implanted with three clips and one patient was implanted with four clips. The mean mitral valve gradient was 3.7 mmHg ± 1.7 and there was no significant difference based on LVEF.

Hemodynamic features from presentation to discharge were improved in both groups. Left atrial V-Wave was reduced from 45.1 ± 15.9 mmHg to 20.2 ± 7.0 mmHg, \( p < 0.01 \) in the LVEF < 35% group and from 31.3 ± 17.1 mmHg to 17.1 ± 5.7 mmHg, \( p < 0.01 \), in the LVEF ≥ 35% group (Figure 2a). There was no significant change in EF from presentation to discharge in either group (26% to 27%, \( p = 0.18 \) and 44% to 45%, \( p = 0.31 \), respectively) (Figure 2b). SPAP reduction was observed in both groups from presentation to discharge (54.1 ± 14.8 mmHg to 43.9 ± 16.3 mmHg, \( p < 0.01 \), in the LVEF < 35% group and from 52.9 ± 22.8 mmHg to 41.7 ± 21.7 mmHg, \( p < 0.01 \), in the LVEF ≥ 35% group) (Figure 3a). Major complications following the procedure were relatively low in both groups (7% vs. 9%, \( p = 0.70 \)).
3a). Major complications following the procedure were relatively low in both groups (7% vs. 9%, \( p = 0.70 \)).

Figure 1. MR grades at presentation, discharge, 3-month and 1-year follow-up. MR was significantly reduced from presentation to discharge in both LVEF groups. MR reduction remains consistent after discharge and throughout follow-up in both groups.

Figure 2. Cont.
Figure 2. Left Ventricle Ejection Fraction (LVEF) and Left Atrial Pressure (LAP) before and after the procedure. (a) There was no significant change in Left ventricle ejection fraction (LVEF) before and after MitraClip procedure in both LVEF < 35% and LVEF ≥ 35% groups; (b) There was a significant reduction in LAP before and after MitraClip procedure in both LVEF < 35% and LVEF ≥ 35% groups.

3.3. Mortality Analysis

In-hospital mortality was low in both the LVEF < 35% and LVEF ≥ 35% groups (11% vs. 7%, $p = 0.51$). One-year mortality was also low and non-significant when comparing the two groups (19% vs. 12%, $p = 0.49$). Age-adjusted survival curves for mortality are shown in Figure 4. There was no significant difference between the two groups at the 1-year follow-up (Log Rank, $p = 0.221$).

(a) sPAP

Figure 3. Cont.
Figure 3. Clinical and Echocardiographic evaluation at presentation, discharge, 3-month and 1-year follow-up. (a) Systolic Pulmonary Artery Pressure (sPAP) was significantly reduced from presentation to discharge in both LVEF groups. sPAP reduction from presentation to 1-year follow up was consistent only for patients in the LVEF > 35%. (b) NYHA class was significantly improved from presentation to discharge in both LVEF groups. NYHA class improvement remain consistent throughout follow-up in both groups; 36 out of 42 patients in the LVEF < 35% group and 51 out of 54 patients in the LVEF ≥ 35% group had NYHA functional class I or class II at 3-month follow up.

3.4. Follow-Up

The median follow-up period was 12 months (IQR 6 to 21).

Follow-up echocardiography after the procedure demonstrated non-significant change in MR from discharge to 3-month and 1-year follow up (Figure 1). This may indicate the durability of the MitraClip procedure, regardless of LV function. Patients benefited from a considerable improvement in functional capacity after the procedure. This improvement was observed throughout the follow-up period (Figure 3b).

As mentioned, significant reduction in sPAP was achieved in both groups after the procedure. During follow-up (3-month and 1-year), there was no significant change in sPAP between the two groups. However, when comparing the pre-procedure sPAP with 1-year sPAP, patients in the LVEF < 35% group did not benefit from sustainable reduction (54 mmHg and 52 mmHg, \( p = 0.85 \)), as opposed to patients in the LVEF ≥ 35% group (53 mmHg to 39 mmHg, \( p < 0.01 \)). This change in hemodynamics between the groups was not translated to a change in functional class at 3-month and 1-year follow-up. Rehospitalization rates at 3-month follow-up were also comparable (19% vs. 16%, \( p = 0.77 \)).
was not associated with lower or higher mortality rate, Log Rank, $p = 0.221$.

4. Discussion

In this international multicenter study, we collected the largest published series of patients who underwent the MitraClip procedure after acute MI complicated by severe MR. We aimed to compare the feasibility of PMVR in patients according to their EF.

There were few significant differences in the basic characteristics between the two EF groups, namely, age and BMI. Almost half of patients required mechanical support and/or were treated with inotropes. In the majority of patients, the salvage MitraClip procedure significantly decreased the MR, as well as the pulmonary hypertension and left atrial V wave; this therefore allowed recovery. Procedural complications were rare, and the clinical condition of most patients was significantly improved as a result of the mitral valve repair. The clinical benefit was maintained through follow up evaluation.

Primary mitral regurgitation in the acute setting is usually due to complete or partial papillary muscle rapture, secondary to ischemia or necrosis, resulting in prolapse or flail leaflet. This condition is accompanied with rapid deterioration and often requires urgent intervention.

Ischemic MR is caused by left ventricular global or regional pathological remodeling due to acute or chronic coronary artery disease [19]. The prevalence of this condition varies between studies and reaches 50% of all MI patients in some series [20]. MR is a central component of the vicious cycle of LV remodeling and HF in MI patients. The regurgitation raises the volume overload and ventricular wall stress, causing further LV dilatation that worsens the MR [19]. Solid data suggests that FMR on presentation, or persistent ischemic FMR, is a negative prognostic factor that is associated with worsened short-term and long-term prognosis [20,21].

Ischemic FMR occurs more frequently with inferior infarction due to geometric distortion in the region of the papillary muscle [22]. Interestingly, in our cohort, 50% of patients presented with anterior MI, suggesting that FMR that is associated with anterior wall infarctions is more likely to require salvage mitral valve intervention. A possible explanation for this is that an anterior wall MI involves more dysfunctional LV and a larger infarct size that causes apical tethering of the valve compared with the localized infarction of the inferior wall. Indeed, MR complicating anterior STEMI was shown to be associated with worse short-term and long-term outcomes than inferior wall infarct [23]. Previous
studies have shown that patients at higher risk of developing ischemic FMR are elderly females who have lower EF and multi-vessel CAD [24]. It is reasonable to assume that EF is an important predictor of outcomes after MI and, indeed, data from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry [25] suggests that EF is directly associated with outcomes among patients after MI: the risk of 1-year mortality was 29.0% in patients with $EF \leq 35\%$, compared with 13.0% in patients with $EF \geq 55\%$. On the other hand, Gerber et al. evaluated the prognostic impact of HF after MI in more than 2500 patients and found that mortality was related to HF but did not differ by EF [26].

In the German transcatheter mitral valve interventions (TRAMI) registry, patients were divided into three groups: LVEF < 30%, LVEF 30–50% and LVEF < 50%. It was concluded that the clinical benefit to patients with severely reduced LV function was comparable to patients with preserved LV. In this registry, over 80% of patients in the LVEF < 30% had functional MR. In a recent study published by Pascual et al., patients were divided according to LVEF above and below 30% and showed that patients in the LVEF > 30% group had better clinical outcomes [10].

We found that patients with severe acute MR and LVEF < 35% had similar mortality rates to patients with LVEF $\geq 35\%$. This finding may suggest that, rather than low EF, severe acute MR is the dominant factor in deterioration and clinical instability and should therefore be treated regardless of EF. However, we cannot exclude that the similar survival rates were related to a lack of statistical power. Revascularization for acute MI can provide improvement of LV function and may decrease the ischemic FMR. Nishino et al. showed that shorter reperfusion time and successful revascularization at presentation were the independent predictors of improvement in FMR [21]. The Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study showed that a short time to revascularization (<2.5 h) independently predicts reverse remodeling which affects the magnitude of FMR [27].

While the negative prognostic effect of ischemic FMR is well recognized, the impact of surgical repair of MR on LV remodeling and outcomes is still controversial, especially in patients with severely reduced LV function, who are poor candidates for surgery [28–30]. Theoretically, the less invasive MitraClip procedure may be considered as an alternative to surgery in high-risk patients. In fact, recent trials suggest that MitraClip therapy improves quality of life and may even reduce mortality among patients with severe chronic ischemic MR [4,6]. However, in most of these clinical trials, patients who had acute or subacute MR due to a recent MI were excluded.

The impact of MitraClip in an acute setting was initially only evaluated in case reports and a small case series [31–34]. The two largest case series were previously published by our group [13,14]. Our findings confirm that MitraClip is a safe and effective procedure in acute settings for a selected high-risk group, both with LVEF < 35% and LVEF $\geq 35\%$, and that in most of the patients the effectiveness of mitral intervention was sustainable in long term follow up.

The study has several limitations that merit consideration. First, although several centers were involved, the sample size is relatively small, and the results should be interpreted with caution. Second, our analysis used retrospectively analyzed observational data and therefore the associations between baseline characteristics and outcomes may be confounded by unmeasured variables. Third, in all our cases, MitraClip was performed as a salvage procedure in acutely ill patients. Therefore, the findings cannot be generalized for stable patients who develop ischemic FMR after MI.

Large, multicenter and randomized trials are needed to confirm this data among acute ischemic FMR.

5. Conclusions

MitraClip intervention in patients with acute severe FMR due to a recent MI in an acute setting is safe and feasible. Even patients with severe LV dysfunction may benefit from transcatheter mitral valve intervention and should not be excluded.
**Author Contributions:** Conceptualization, D.H., R.E.-L., D.D., M.T. and M.S.; methodology, D.D. and L.K.; validation, D.D. and M.T.; formal analysis, D.H. and R.E.-L.; investigation, D.H., R.E.-L., T.B.-G., P.D., D.A., M.A., X.F., L.N.-F., P.V., L.K., N.F., K.S., A.C., I.P., F.P., D.S. (Doron Sudarsky), A.K., V.N., M.G., R.B., L.P. (Leor Perl), H.D., L.P. (Lion Poles), S.S. (Sara Shimoni), S.G., B.C.-Q., S.S. (Salvatore Scianna), I.M., D.S. (Davide Schiavi), C.S., N.C., J.E.-M., M.C., E.F.-P., M.D.P., A.R., C.V.-U., A.I.-R., E.F.-V., D.D., M.T. and M.S.; data curation, D.H.; writing—original draft preparation, D.H. and M.S.; writing—review and editing, R.E.-L., D.D. and M.T.; visualization, D.H. and M.S.; supervision, R.E.-L., D.D., M.T. and M.S.; project administration, D.H. and M.S.; funding acquisition, L.P. (Lion Poles) and M.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki Ethical Principles and was approved by individual local ethics committees (KMC-68-2010).

**Informed Consent Statement:** All patients provided written informed consent prior to the intervention.

**Data Availability Statement:** The data that supports the findings of this study are available from the corresponding author, D.H., upon reasonable request.

**Conflicts of Interest:** Dan Haberman is an Abbott CEC member. Rodrigo Estévez-Loureiro, Dabif Arzamendi, Paolo Denti, Xavier Freixa, are consultants for Abbott. Andrew Czarnecki received speaker fee from Abbott and consultant for Caisson Interventional and Baylis Medical. Marco Gennari is consultant for Medtronic. Luis Nombela-Franco has served as a proctor of Abbott Vascular and received speakers’ honoraria from Boston Scientific and Abbott Vascular. Francesco Maisano has served as a consultant for Abbott Vascular, Edwards Lifesciences, Cardiovalve, Valtech, and Medtronic; and is co-founder of 4tech. Maurizio Taramasso is Consultant for Abbott, Boston Scientific, 4tech and receives personal fees from Edwards Lifescience, CoreMedic, Swissvortex and Mitraltech. Mony Shuvy is a proctor and consultant for Abbott and consultant for Edwards Lifesciences. All other authors have reported that they have no relationship relevant to the contents of this paper to disclose.

**References**

1. Bhardwaj, B.; Sidhu, G.; Balla, S.; Kumar, V.; Kumar, A.; Aggarwal, K.; Dohrmann, M.L.; Alpert, M.A. Outcomes and Hospital Utilization in Patients with Papillary Muscle Rupture Associated with Acute Myocardial Infarction. *Am. J. Cardiol.* 2020, 125, 1020–1025. [CrossRef]

2. Rossi, A.; Dini, F.L.; Faggiano, P.; Agricola, E.; Cicoira, M.; Frattini, S.; Simioniciuc, A.; Gullace, M.; Ghio, S.; Enriquez-Sarano, M.; et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. *Heart* 2011, 97, 1675–1680. [CrossRef] [PubMed]

3. Grigioni, F.; Enriquez-Sarano, M.; Zehr, K.J.; Bailey, K.R.; Tajik, A.J. Ischemic mitral regurgitation: Long-term outcome and prognostic implications with quantitative Doppler assessment. *Circulation* 2001, 103, 1759–1764. [CrossRef]

4. Maisano, F.; Franzén, O.; Baldus, S.; Schafer, U.; Hausleiter, J.; Butter, C.; Ussia, G.P.; Sievert, H.; Richardt, G.; Widder, J.D.; et al. Percutaneous mitral valve interventions in the real world: Early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. *J. Am. Coll. Cardiol.* 2013, 62, 1052–1061. [CrossRef] [PubMed]

5. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.; Coats, A.J.; Falk, V.; Gonzalez-Juanatey, J.R.; Harjola, VP.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur. J. Heart Fail.* 2016, 18, 891–975. [CrossRef]

6. Geis, N.A.; Puls, M.; Lubos, E.; Zuern, C.S.; Franke, J.; Schueler, R.; von Bardeleben, R.S.; Boekstegers, P.; Ouarrak, T.; Zahn, R.; et al. Safety and efficacy of MitraClip therapy in patients with severely impaired left ventricular ejection fraction: Results from the German transcatheter mitral valve interventions (TRAMI) registry. *Eur. J. Heart Fail.* 2018, 20, 598–608. [CrossRef] [PubMed]

7. Kalbacher, D.; Schafer, U.; RS, V.B.; Eggebrecht, H.; Sievert, H.; Nickenig, G.; Butter, C.; May, A.E.; Bekeredjian, R.; Ouarrak, T.; et al. Long-term outcome, survival and predictors of mortality after MitraClip therapy: Results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry. *Int. J. Cardiol.* 2019, 277, 35–41. [CrossRef] [PubMed]

8. Stone, G.W.; Lindenfeld, J.; Abraham, W.T.; Kar, S.; Lim, D.S.; Mishell, J.M.; Whisenant, B.; Grayburn, P.A.; Rinaldi, M.; Kapadia, S.R.; et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. *N. Engl. J. Med.* 2018, 379, 2307–2318. [CrossRef] [PubMed]

9. Obadia, J.F.; Messika-Zeitoun, D.; Leurent, G.; Jung, B.; Bonnet, G.; Piriou, N.; Lefevere, T.; Piot, C.; Rouleau, F.; Carrie, D.; et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. *N. Engl. J. Med.* 2018, 379, 2297–2306. [CrossRef] [PubMed]
10. Pascual, I.; Benito-González, T.; Hernandez-Vaquero, D.; Estévez-Loureiro, R.; Lorca, R.; Garrote-Coloma, C.; Avanzas, P.; Gualis, J.; Adeba, A.; de Prado, A.P.; et al. Percutaneous treatment with Mitraclip for functional mitral regurgitation: Medium-term follow up according to left ventricular function. Ann. Transl. Med. 2020, 8, 959. [CrossRef]

11. Otto, C.M.; Nishimura, R.A.; Bonow, R.O.; Carabello, B.A.; Erwin, J.P., 3rd; Gentile, F.; Jneid, H.; Krieger, E.V.; Mack, M.; McLeod, C.; et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021, 143, e72–e227.

12. Pighi, M.; Estevéz-Loureiro, R.; Maisano, F.; Ussia, G.P.; Dall’Ara, G.; Fransen, O.; Laroche, C.; Settgren, M.; Winter, R.; Nickenig, G.; et al. Immediate and 12-Month Outcomes of Ischemic Versus Nonischemic Functional Mitral Regurgitation in Patients Treated with MitraClip (from the 2011 to 2012 Pilot Sentinel Registry of Percutaneous Edge-To-Edge Mitral Valve Repair of the European Society of Cardiology). Am. J. Cardiol. 2017, 119, 630–637. [PubMed]

13. Haberman, D.; Taramasso, M.; Czarnecki, A.; Kerner, A.; Chrissoheris, M.; Spargas, K.; Poles, L.; Agmon, Y.; Sciami, S.; Beeri, R.; et al. Salvage MitraClip in severe secondary mitral regurgitation complicating acute myocardial infarction: Data from a multicentre international study. Eur. J. Heart Fail. 2019, 21, 1161–1164. [CrossRef] [PubMed]

14. Estevez-Loureiro, R.; Adamo, M.; Arzamendi, D.; Denti, P.; Freixa, X.; Nombela-Franco, L.; Pascual, I.; Melica, B.; Attias, D.; Serrador, A.; et al. Transcatheter mitral valve repair in patients with acute myocardial infarction: Insights from the European Registry of MitraClip in Acute Mitral Regurgitation following an acute myocardial infarction (EREMMI). Eurointerv. J. Eur. Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol. 2020, 15, 1248–1250. [CrossRef] [PubMed]

15. Estevéz-Loureiro, R.; Shuvy, M.; Taramasso, M.; Benito-Gonzalez, T.; Denti, P.; Arzamendi, M.; Adamo, M.; Freixa, X.; Villablacana, P.; Krivoshei, L.; et al. Use of MitraClip for mitral valve repair in patients with acute mitral regurgitation following acute myocardial infarction: Effect of cardiogenic shock on outcomes (IREMMI Registry). Catheter. Cardiovasc. Interv. Off. J. Soc. Card. Angiogr. Interv. 2021. [CrossRef]

16. Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afilalo, J.; Armstrong, A.; Erande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2015, 28, 1–39.e14. [CrossRef]

17. Zoghbi, W.A.; Adams, D.; Bonow, R.O.; Enriquez-Sarano, M.; Foster, E.; Grayburn, P.A.; Hahn, R.T.; Han, Y.; Hung, J.; Lang, R.M.; et al. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J. Am. Soc. Echocardiogr. 2017, 30, 303–371. [CrossRef]

18. Stone, G.W.; Adams, D.H.; Abraham, W.T.; Kappetein, A.P.; Généreux, P.; Vranckx, P.; Mehran, R.; Kuck, K.H.; Leon, M.B.; Piazza, N.; et al. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: Part 2: Endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium. Eur. Heart J. 2015, 36, 1878–1891. [CrossRef] [PubMed]

19. Bursi, F.; Enriquez-Sarano, M.; Kwon, V.T.; Jacobsen, S.J.; Weston, A.; Meisner, R.A.; Roger, V.L. Heart failure and death after medically defined mitral regurgitation early after acute myocardial infarction. Am. Heart J. 2015, 169, 1268–1275. [CrossRef]

20. Hillis, G.S.; Moller, J.E.; Pellikka, P.A.; Bell, M.R.; Casalang-Verzosa, G.C.; Oh, J.K. Prognostic significance of echocardiographically defined mitral regurgitation early after acute myocardial infarction. Am. Heart J. 2005, 150, 1268–1275. [CrossRef]

21. Nishino, S.; Watanabe, N.; Kimura, T.; Enriquez-Sarano, M.; Nakama, T.; Furugen, M.; Winter, R.; Nickenig, G.; et al. Percutaneous treatment with Mitraclip for functional mitral regurgitation: Medium-term follow up according to left ventricular function. Ann. Transl. Med. 2020, 8, 959. [CrossRef]

22. Sutton, N.R.; Li, S.; Thomas, L.; Wang, T.Y.; de Lemos, J.A.; Enriquez-Sarano, J.R.; Shah, R.U.; Fonarow, G.C. The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG) Medicare-linked database. Am. Heart J. 2016, 178, 65–73. [CrossRef]

23. Gerber, Y.; Weston, S.A.; Enriquez-Sarano, M.; Berardi, C.; Chamberlain, A.M.; Manemann, S.M.; Jiang, R.; Dunlay, S.M.; Roger, V.L. Mortality Associated with Heart Failure after Myocardial Infarction: A Contemporary Community Perspective. Circ. Heart Fail. 2016, 9, e004640. [CrossRef]

24. Funaro, S.; La Torre, G.; Madonna, M.; Galucho, L.; Scara, A.; Labbadia, A.; Canali, E.; Mattatteli, A.; Fedele, F.; Alessandri, F.; et al. Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: Results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur. Heart J. 2009, 30, 566–575. [CrossRef] [PubMed]
28. Agricola, E.; Oppizzi, M.; Pisani, M.; Meris, A.; Maisano, F.; Margonato, A. Ischemic mitral regurgitation: Mechanisms and echocardiographic classification. *Eur. J. Echocardiogr.* **2008**, *9*, 207–221. [CrossRef] [PubMed]

29. Mentias, A.; Raza, M.Q.; Barakat, A.F.; Hill, E.; Youssef, D.; Krishnaswamy, A.; Desai, M.Y.; Griffin, B.; Ellis, S.; Menon, V.; et al. Outcomes of ischaemic mitral regurgitation in anterior versus inferior ST elevation myocardial infarction. *Open Heart* **2016**, *3*, e000493. [CrossRef] [PubMed]

30. Chan, K.M.; Punjabi, P.P.; Flather, M.; Wage, R.; Symmonds, K.; Roussin, I.; Rahman-Haley, S.; Pennell, D.J.; Kilner, P.J.; Dreyfus, G.D.; et al. Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: Final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. *Circulation* **2012**, *126*, 2502–2510. [CrossRef] [PubMed]

31. Estevez-Loureiro, R.; Arzamendi, D.; Freixa, X.; Cardenal, R.; Carrasco-Chinchilla, F.; Serrador-Frutos, A.; Pan, M.; Sabate, M.; Diaz, J.; Hernandez, J.M.; et al. Percutaneous Mitral Valve Repair for Acute Mitral Regurgitation after an Acute Myocardial Infarction. *J. Am. Coll. Cardiol.* **2015**, *66*, 91–92. [CrossRef] [PubMed]

32. Wolff, R.; Cohen, G.; Peterson, C.; Wong, S.; Hockman, E.; Lo, J.; Strauss, B.H.; Cohen, E.A. MitraClip for papillary muscle rupture in patient with cardiogenic shock. *Can. J. Cardiol.* **2014**, *30*, 1461.e13–1461.e14. [CrossRef] [PubMed]

33. Rodriguez-Santamarta, M.; Estevez-Loureiro, R.; Gualis, J.; Alonso, D.; Perez de Prado, A.; Fernandez-Vazquez, F. Percutaneous mitral valve repair with MitraClip system in a patient with acute mitral regurgitation after myocardial infarction. *Rev. Esp. Cardiol.* **2015**, *68*, 259–261. [CrossRef] [PubMed]

34. Adamo, M.; Curello, S.; Chiari, E.; Fiorina, C.; Chizzola, G.; Magatelli, M.; Locantore, E.; Cuminetti, G.; Lombardi, C.; Manzato, A.; et al. Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience. *Int. J. Cardiol.* **2017**, *234*, 53–57. [CrossRef]